GuopingDa Ph.D.


Shanghai + 86.21.2201.8085

Guoping Da, an IP litigator and counselor, represents multinational companies in IP enforcement and infringement actions in the United States and China. These representations have involved a broad range of technologies such as biotechnology, pharmaceuticals, animal health products, optics, computer hardware and software, and vehicle telematics. Guoping also has extensive experience in the area of trade secrets, and she published an article regarding strategies for trade secret protection in China.

Guoping is experienced in assisting clients in technology transfer transactions. Her recent representative experience includes: Incyte's strategic collaboration and license agreement with Innovent for the China rights of certain clinical stage pharmaceutical candidates; Incyte's sublicense out to Zai Lab of certain intellectual property rights in China to an anti-PD1 molecule; and Huadong Medicine's subscription of Series B preferred shares of R2 Dermatology and the distribution agreement between R2 and Huadong regarding a medical device product.

Guoping also assists multinational companies on compliance and corruption matters. Her experience includes advising clients on Foreign Corrupt Practices Act (FCPA) issues and conducting related investigations, providing compliance training for clients operating in China, and conducting anticorruption due diligence for inbound investment.

Guoping's Ph.D. thesis focused on structure determination and function characterization of gene regulatory proteins, including histone deacetylases and histone demethylases. As such, she is familiar with a broad range of molecular, biochemical, and biophysical research tools centered around X-ray crystallography and structure-based drug design.


  • Huadong Medicine enters co-development partnership with Exscientia to accelerate oncology drug discovery through AIJones Day advised Huadong Medicine Co. Ltd. in the negotiation and signing of a research cooperation agreement with Exscientia, a world-leading, clinical-stage Artificial Intelligence (AI) drug discovery company.
  • Chinese financial leasing company provides $15 million loan to KateevaJones Day represented a Chinese financial leasing company in connection with its $15 million loan provided to Kateeva Inc., a developer of the world's first inkjet printer to manufacture high volumes of flexible OLEDs (organic electroluminescent diodes).
  • Chinese financial institution responds to subpoena for records in major U.S. investigationJones Day represented a Chinese financial institution in a matter relating to a significant U.S. government investigation.
  • SharkNinja defends against FTI's claims relating to vacuum cleaner technologyJones Day defended SharkNinja Operating LLC against Flexible Technologies, Inc.'s claims of patent infringement, misappropriation of trade secrets, and breach of a confidentiality agreement relating to the development of an electrified stretch e-hose for SharkNinja vacuum cleaners.
  • Incyte grants license to and collaborates with Zai Lab to develop and commercialize anti-PD1 pharmaceutical products in ChinaJones Day represented Incyte Corporation in its sublicense out to Zai Lab Limited of certain intellectual property rights to an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively developing in the U.S. and other jurisdictions outside of China.
  • Huadong Medicine invests in R2 Dermatology and enters into distribution agreementJones Day advised Huadong Medicine Co. Ltd., a Chinese manufacturer and distributor of pharmaceutical and other medical products, in connection with its subscription of Series B Preferred Shares of R2 Dermatology, Inc., and the negotiation of a distribution agreement authorizing Huadong Medicine as an exclusive distributor in Asia for R2's skin whitening products.
  • China UnionPay joins other major technology players in Open Invention Network communityJones Day assisted China UnionPay Co., Ltd.'s diligence on the Open Invention Network ("OIN") community's cross-licensing agreement, which creates a zone of patent nonaggression for certain core Linux kernel technology.
  • Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in ChinaJones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases.
  • Sequoia China invests in HiFiBiO TherapeuticsJones Day represented Sequoia China in connection with its purchase of Series B Convertible Preferred Stock in a private placement by HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis.
  • New Enterprise Associates invests in TuyaJones Day represented New Enterprise Associates in connection with its investment in Tuya Inc., a China-based technology company.
  • Public U.S. manufacturer operating in China investigates allegations of misconduct concerning interactions with state-owned customers and customs officialsJones Day assisted a public U.S. manufacturer in investigating allegations of misconduct concerning employees, distributors, and other third party intermediaries interacting with state-owned customers and customs officials in China.
  • Public life sciences company conducts anti-corruption due diligence on multiple acquisition targets in ChinaJones Day counseled a public U.S. life sciences company with respect to anti-corruption due diligence on more than a dozen acquisition targets operating in China.
  • Multinational company reports results of internal investigation of alleged FCPA violations to SEC, which takes no actionOn behalf of a multinational company doing business in oil and gas in the Asia-Pacific, South America, and Mexico, Jones Day conducted an internal investigation into allegations of corrupt payments made to procure business.
  • Hyundai fends off patent infringement action related to vehicle telematicsJones Day successfully represented Hyundai Motor America in a patent infringement suit filed in the District of Minnesota related to vehicle telematics. 
  • Essilor International defends against patent infringement action brought by Hoya CorporationJones Day represented Essilor International and its subsidiaries regarding the alleged infringement of two patents related to various aspects of lens manufacturing.
  • Merial and BASF AGRO resolve patent infringement action against Virbac involving FRONTLINE® productsJones Day obtained a settlement for Merial Limited and BASF AGRO B.V., Arnheim (NL), Wädenswil Branch, in a patent infringement action against Virbac, a French animal pharmaceutical company, in the Northern District of Texas.
  • Sensus defends against patent infringement claims brought by EON Corp. involving smart grid technologyJones Day represented Sensus USA, Inc. and Sensus Metering Systems, Inc. in a patent infringement action related to smart grid power technology.
  • IBM defends against patent infringement action related to computer systems and softwareJones Day represented defendant International Business Machines Corporation in a patent infringement case related to computer systems, applications, and security management software.
  • Celgene files declaratory judgment action against CyclacelJones Day represents plaintiff Celgene Corporation in a declaratory judgment action for non-infringement and invalidity of four Cyclacel Pharmaceuticals, Inc. patents related to certain depsipeptides and uses thereof.
  • Speaking Engagements

    • 2016年1月18日
    • January 18, 2016
      Fee Shifting Strategies for Patent Troll Litigation and IP Review in M&A Transactions
    • 2016年1月18日